All In Biotech

Drug Trial Radar · NCT07286331

A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)

A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Jun 4, 2026

Primary completion

Feb 29, 2028

Study completion May 30, 2029

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
ENGOT, GOG, APGOT
First posted
Dec 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating Endometrial Cancer (EC) compared to standard of care. The study also assesses whether Mo-Rez is safe and tolerated well by participants in comparison to standard of care and will help provide a better understanding of the main side effects of the drugs.

Conditions

  • Neoplasms, Endometrial

Interventions

  • Mocertatug rezetecanDrug

    Mocertatug rezetecan will be administered

  • PaclitaxelDrug

    Paclitaxel will be administered

  • DoxorubicinDrug

    Doxorubicin will be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR) by BICRTime frame: Up to approximately 97 weeks
  2. Progression Free Survival (PFS) by BICRTime frame: Up to approximately 97 weeks

Locations

56 sites in 10 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama · Recruiting

  • GSK Investigational Site

    Omaha, Nebraska · Recruiting

  • GSK Investigational Site

    Sugar Land, Texas · Recruiting

  • GSK Investigational Site

    Charlottesville, Virginia · Recruiting

  • GSK Investigational Site

    Buenos Aires, Argentina · Recruiting

  • GSK Investigational Site

    Ciudad Autonoma de Buenos Aire, Argentina · Recruiting

  • GSK Investigational Site

    Ciudad Autonoma de Buenos Aire, Argentina · Recruiting

  • GSK Investigational Site

    Córdoba, Argentina · Recruiting

  • GSK Investigational Site

    Rosario, Argentina · Recruiting

  • GSK Investigational Site

    Florida, Buenos Aires, Argentina · Recruiting

  • GSK Investigational Site

    Mendoza, MD, Argentina · Recruiting

  • GSK Investigational Site

    Dubbo, New South Wales, Australia · Recruiting

  • GSK Investigational Site

    Auchenflower, Queensland, Australia · Recruiting

  • GSK Investigational Site

    Herston, Queensland, Australia · Recruiting

  • GSK Investigational Site

    CuritibaPR, Brazil · Recruiting

  • GSK Investigational Site

    Porto Alegre, Brazil · Recruiting

  • GSK Investigational Site

    São Paulo, Brazil · Recruiting

  • GSK Investigational Site

    São Paulo, Brazil · Recruiting

  • GSK Investigational Site

    Vitória, Brazil · Recruiting

  • GSK Investigational Site

    São Luís, Maranhão, Brazil · Recruiting

  • GSK Investigational Site

    Toronto, Ontario, Canada · Recruiting

  • GSK Investigational Site

    Montreal, Quebec, Canada · Recruiting

  • GSK Investigational Site

    Montreal, Quebec, Canada · Recruiting

  • GSK Investigational Site

    Haifa, Israel · Recruiting

  • GSK Investigational Site

    Haifa, Israel · Recruiting

  • GSK Investigational Site

    Kfar Saba, Israel · Recruiting

  • GSK Investigational Site

    Aichi, Japan · Recruiting

  • GSK Investigational Site

    Fukuoka, Japan · Recruiting

  • GSK Investigational Site

    Hokkaido, Japan · Recruiting

  • GSK Investigational Site

    Hyōgo, Japan · Recruiting

  • GSK Investigational Site

    Kanagawa, Japan · Recruiting

  • GSK Investigational Site

    Kanagawa, Japan · Recruiting

  • GSK Investigational Site

    Kyoto, Japan · Recruiting

  • GSK Investigational Site

    Mie, Japan · Recruiting

  • GSK Investigational Site

    Numakunai, Japan · Recruiting

  • GSK Investigational Site

    Okayama, Japan · Recruiting

  • GSK Investigational Site

    Okinawa, Japan · Recruiting

  • GSK Investigational Site

    Osaka, Japan · Recruiting

  • GSK Investigational Site

    Saitama, Japan · Recruiting

  • GSK Investigational Site

    Shizuoka, Japan · Recruiting

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.